Investment Thesis
Inmune Bio is a pre-revenue biotech company with negligible revenue ($50K) and substantial operating losses ($5.8M), burning $3.4M annually in cash. While the company maintains a reasonable cash position ($21.4M, ~6 years runway) and strong liquidity (4.24x current ratio), the absence of meaningful commercialization progress and negative cash flow trajectory indicate significant execution risk without evidence of near-term revenue inflection.
Strengths
- Strong cash position of $21.4M provides adequate operating runway (6+ years at current burn rate)
- Excellent liquidity with current ratio of 4.24x indicates strong ability to meet short-term obligations
- Low financial leverage (Debt/Equity 0.76x) limits solvency risk and provides refinancing flexibility
Risks
- Negative operating cash flow of $3.4M annually indicates ongoing cash burn with no near-term path to profitability
- Negligible revenue of $50K demonstrates lack of meaningful commercialization; insufficient to offset R&D expenses
- Will require additional financing or revenue generation within 6 years; no insider buying activity signals limited confidence from management
Key Metrics to Watch
- Quarterly revenue growth trajectory and customer acquisition
- Quarterly operating cash burn rate relative to cash reserves
- Clinical trial progress, regulatory milestones, and pipeline advancement metrics
Financial Metrics
Revenue
50.0K
Net Income
-5.4M
EPS (Diluted)
$-0.20
Free Cash Flow
-4.4M
Total Assets
25.8M
Cash
21.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-11,624.0%
Net Margin
-10,814.0%
ROE
-27.6%
ROA
-20.9%
FCF Margin
-8,890.0%
Balance Sheet & Liquidity
Current Ratio
4.24x
Quick Ratio
4.24x
Debt/Equity
0.76x
Debt/Assets
24.0%
Interest Coverage
N/A
Long-term Debt
15.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T11:13:23.458061 |
Data as of: 2026-03-31 |
Powered by Claude AI